Novak Djokovic He is one of only three players in the top 100 of the Association of Tennis Professionals (ATP) and the Women’s Tennis Association (WTA) who have not been fully vaccinated against covid-19, which has already affected their participation in the Australian Open and is expected to be repeated in the second Grand Slam of the year, Roland Garros. Far from accessing the vaccine, the Serb and his wife decided to finance a treatment against covid-19 from the QuantBioRes biotechnology company.
The ATP and the WTA confirmed that 98 and 99 of their respective top 100 had been fully vaccinated before the Australian Open. Djokovic and the american Tennys Sandgren, on the men’s tour, have refused to receive the dose, while it is unknown who is the tennis player in the women’s branch who has not been inoculated.
The country’s strict border controls had a strong impact on the vaccination rate in a sport in which, until before US Open As of August, half of the players had not been fully vaccinated. The Greek, Stefanos Tsitsipas, was one of those who declared that he would access the vaccine only if it was mandatory to compete.
This mandate is already being extended after the saga that starred the number one tennis player in the world, Djokovic, whose exemption to compete at the Australian Open was revoked, forcing his deportation from the country due to his unvaccinated status. In this regard, tennis players such as Victoria Azarenka, a member of the WTA Players Council, expressed that “in certain things, I think a black and white approach is necessary.”
Less than 24 hours after the Serbian tennis player’s deportation, the French government, headquarters of Roland Garros from May 22 to June 5, it also approved the compulsory vaccination certificate for all those who enter an establishment that receives public, including the Grand Slam of tennis.
If not vaccinated, these measures will lengthen the wait for Djokovic for his 21st title in this category. But far from agreeing to receive the inoculation, the Serbian decided to buy 80% of a Danish biotech firm, QuantBioRes, which aims to develop a treatment to counteract Covid-19.
Ivan Loncarevic, director of the company, explained to Reuters that the company is developing a peptide that can block the infection mechanism between the coronavirus and our cells. In addition, it hopes to launch clinical trials in Britain this summer. The businessman emphasized that the firm was working on a treatment, not a vaccine.